What You Have to Know

Cardinal Well being, Inc. (CAH), headquartered in Dublin, Ohio, operates as a healthcare providers and merchandise firm. Valued at $48.8 billion by market cap, the corporate’s providers embody pharmaceutical distribution, health-care product manufacturing, distribution and consulting providers, drug supply programs improvement, pharmaceutical packaging, automated dishing out programs manufacturing, and retail pharmacy franchising. The healthcare large is anticipated to announce its fiscal second-quarter earnings for 2026 within the close to time period.

Forward of the occasion, analysts count on CAH to report a revenue of $2.31 per share on a diluted foundation, up 19.7% from $1.93 per share within the year-ago quarter. The corporate has persistently surpassed Wall Road’s EPS estimates in its final 4 quarterly reviews.

For the complete 12 months, analysts count on CAH to report EPS of $9.86, up 19.7% from $8.24 in fiscal 2025. Its EPS is anticipated to extend 10.6% 12 months over 12 months to $10.90 in fiscal 2027.

CAH inventory has considerably outperformed the S&P 500 Index’s ($SPX) 16.4% features over the previous 52 weeks, with shares up 74.3% throughout this era. Equally, it significantly outperformed the Well being Care Choose Sector SPDR Fund’s (XLV) 12.8% returns over the identical timeframe.

CAH’s sturdy efficiency is pushed by the Solaris Well being acquisition, including 750+ suppliers to its MSO platform, and strong natural progress in prescription drugs, generics, and specialty options. New buyer wins, price controls, and investments in automation and logistics are boosting income, with double-digit progress anticipated in specialty platforms like autoimmune, urology, and oncology. With sturdy generic efficiency and a concentrate on MSO platforms and biopharmaceutical options, administration is assured in sustained demand, as mirrored in up to date steerage.

On Oct. 30, CAH shares closed up greater than 15% after reporting its Q1 outcomes. Its adjusted EPS of $2.55 surpassed Wall Road expectations of $2.21. The corporate’s income was $64 billion, beating Wall Road forecasts of $59.1 billion. CAH expects full-year adjusted EPS within the vary of $9.65 to $9.85.

Analysts’ consensus opinion on CAH inventory is bullish, with a “Robust Purchase” score general. Out of 16 analysts overlaying the inventory, 12 advise a “Robust Purchase” score, and 4 give a “Maintain.” CAH’s common analyst worth goal is $216.19, indicating a possible upside of 5.2% from the present ranges.

On the date of publication, Neha Panjwani didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All info and knowledge on this article is solely for informational functions. This text was initially revealed on Barchart.com